Omni MedSci, Inc. v. Oura Health Oy

I'll research this case across the sources you listed.

Case Overview — Omni MedSci, Inc. v. Oura Health Oy, No. 2:26-cv-00289 (E.D. Tex.)

The parties. Omni MedSci, Inc. is a Michigan corporation based at 1718 Newport Creek Drive, Ann Arbor, founded by Dr. Mohammed N. Islam, a University of Michigan electrical-engineering professor and prolific inventor in near-infrared/supercontinuum laser and optical-sensing physics. It does not make or sell wearable devices; it monetizes a large continuation family (earliest priority Dec. 31, 2012, expiring around Dec. 17, 2033) through licensing and litigation, and the Stanford NPE Litigation Database classifies it as "individual-inventor-started" rather than as an operating company. Defendants have characterized it as a non-practicing entity, and the company's litigation history — suits against Apple (E.D. Tex. 2:18-cv-134/429, later N.D. Cal.), Samsung/Fossil/OnePlus/Oura (2:24-cv-01070), WHOOP (D. Del. 1:25-cv-00140), and more recent 2026 filings against Samsung (2:26-cv-00356) and Sony (2:26-cv-00980) — is consistent with that characterization. Oura Health Oy is a Finnish osakeyhtiö headquartered at Elektroniikkatie 10, Oulu, Finland, that designs, markets and imports the Ōura Ring line of finger-worn health-tracking rings, together with the Ōura iOS/Android app and the Ōura Cloud platform. It has no U.S. manufacturing footprint; Omni's jurisdictional theory rests on Oura's authorized U.S. retailers and distributors, and on general venue rules for foreign defendants under 28 U.S.C. § 1391(c)(3) and In re HTC Corp., 889 F.3d 1349 (Fed. Cir. 2018).

The accused technology and the asserted patent. The accused instrumentality is pled as an integrated system: the Ōura Ring (Gen 1, Gen 2, Gen 3 and Gen 4 series), the companion Ōura app, and the Ōura Cloud backend, which together measure heartbeat, blood-oxygen and related parameters optically and ship the data to a phone/tablet and then to the cloud. The technical theory tracks Omni's core family: LED light sources and lenses that deliver light into tissue, spatially separated photodetectors arranged along an arc, an ADC-coupled detection system synchronized to (and modulating) the light source, and signal processing that improves signal-to-noise ratio by differencing a "light-off" (ambient) signal against a "light-on" (reflected) signal — plus wear-state detection and smartphone/tablet communication. Per the case metadata, the sole patent at issue is U.S. Patent No. 11,596,311, a member of that same Dec. 31, 2012-priority continuation chain (the chain that has produced the '868, '533, '484, '304, '455, '790 and '475 patents); the secondary complaint analysis for this docket describes asserted claims 1, 5–8 and 11–13 covering the LED/lens/detector differential-measurement architecture. Caveat: I could not independently confirm from USPTO or Google Patents sources the '311's exact title, issue date or claim text, and the only complaint-level summary I located for this docket reads as a template that partly tracks the '533 claim set — so the one-line technical sketch above should be treated as family-level description rather than verified claim language. Notably, the earlier consolidated case, 2:24-cv-01070, asserted five different patents ('868, '533, '484, '304, '455), not the '311.

Procedural posture and why it matters. The case was filed April 10, 2026 in the Marshall Division of the Eastern District of Texas (the "2:" docket prefix), ten days after Judge Rodney Gilstrap's March 31, 2026 order in Omni MedSci v. Samsung Electronics, No. 2:24-cv-01070-JRG-RSP (Dkt. 163), overruled Omni's objections, adopted Magistrate Judge Roy S. Payne's Report and Recommendation (Dkt. 146), and granted Oura's motion to dismiss the Third Amended Complaint as to improper joinder — the event that appears to have forced Omni to re-file against Oura alone. Given Marshall Division practice and the assignment pattern in the companion case, the matter is most likely before Judge Gilstrap with Magistrate Judge Payne; I could not confirm the assignment from a docket entry and flag it as unverified. Law360's case page associates Mayer Brown attorneys (including Julia Haines) with the Oura defense in the April 10, 2026 filing, while Omni's filings in parallel 2026 cases are signed by William P. Davis; both should be confirmed against PACER appearances. The venue significance is substantial: EDTX Marshall remains the plaintiff-friendliest patent docket in the country, and Oura — a foreign defendant with a large U.S. retail channel but no U.S. plant — cannot easily mount the § 1404/§ 1406 transfer attack that has succeeded for other defendants post-TC Heartland.

The case is notable on several axes. (1) Market context: Oura is the category leader in smart rings, a segment that has become a genuine patent battleground — Samsung's Galaxy Ring launch, Zepp's declaratory-judgment action against Oura (2:26-cv-00316, E.D. Tex.), and the ITC/§ 337 actions Oura itself has brought against smaller rivals. (2) NPE assertion pattern: Omni's continuation strategy mints new claims faster than defendants can invalidate them — the Board invalidated claims 11–12 of the '533 in IPR2019-00916 (FWD Oct. 14, 2020), summarily affirmed at 2022 WL 2062168 (Fed. Cir. June 8, 2022), and held all 23 claims of the '484 unpatentable in IPR2021-00453 (FWD Aug. 3, 2022), reaffirmed on remand (Feb. 14, 2025) with a second Federal Circuit appeal pending at No. 25-1646 — yet the portfolio keeps producing new patents ('790, '475, '311, 12,588,820), which is precisely why a fresh '311 suit can follow a joinder dismissal. (3) IPR linkage: Oura is not merely a district-court defendant; it is a named petitioner alongside Samsung, Fossil and OnePlus in the PTAB campaign against the family — IPR2025-01250 ('533), IPR2025-01252/01253 ('790), IPR2025-01254 ('475

I'll research this case systematically. Let me start with parallel searches on the docket, parties, and patent.

Key finding: the docket is a new 2026 case, distinct from the 2024 consolidated Samsung/Fossil/Oura action. Let me dig into the '311 patent and this specific docket.

Bottom line up front

There is no merits track record to report for Omni MedSci, Inc. v. Oura Health Oy, No. 2:26-cv-00289 (E.D. Tex.) — it is roughly six and a half months old (filed 2026-04-10; today 2026-10-31), still shows as "Open" on docket aggregators, and I found no public record of an answer, counterclaims, a motion to dismiss/transfer/stay, a docket control order, a Markman order, or any trial setting in this case. Anyone telling you otherwise is extrapolating from the related 2024 case.

What does exist is a rich, well-documented record in the parent consolidated action, No. 2:24-cv-01070-JRG-RSP (E.D. Tex., Gilstrap/Payne), from which Oura was dismissed for improper joinder on 2026-03-31 — ten days before this suit was filed — plus a live PTAB program against the same patent family. That context is where the real legal developments are, and I've built the chronology around both, clearly labeled.

---

I. Chronology

A. The parent case: No. 2:24-cv-01070 (background to the 2026 suit)

I'll research the docket and counsel for this case.

Good leads. Now let me pull the actual docket in 2:26-cv-00289 and confirm plaintiff's appearances.

Let me dig into the specific docket and confirm the plaintiff's counsel lineup.

Bottom line first — what is and isn't verified

I could not pull a PACER/CM-ECF docket sheet for 2:26-cv-00289 in this session. The free aggregators that index E.D. Tex. filings (Ex Parte, Patexia) show the case exists — Omni MedSci, Inc. v. Oura Health Oy, NOS 830, filed 04/10/2026, Eastern District of Texas — but none of the sources I could reach discloses the Notice(s) of Appearance or the signature block of Dkt. 1 in this particular case. So I am not going to assert as fact who has formally entered an appearance. What follows distinguishes (a) confirmed counsel of record for Omni MedSci in the immediately related E.D. Tex. litigation, and (b) the one attorney independently linked to this case number by a litigation database.

There is also no indication of sealing on the plaintiff's side (the complaint analysis is publicly digestible), and no indication of in-house counsel appearing for Omni — Omni MedSci is an individual-inventor-started company (Dr. Mohammed N. Islam) and historically litigates entirely through outside counsel.

Plaintiff's counsel — best-supported lineup

Evidence trail and citations

• Case existence / metadata: Ex Parte case page for 2:26-cv-00289, Omni MedSci Inc v. Oura Health Oy — filed 04/10/26, NOS 830, E.D. Tex., status "Open": https://ai-lab.exparte.com/case/dct/txed/2:26-cv-00289/omni-medsci-inc-v-oura-health-oy. Patexia's case index independently lists the same caption and date.
• Maloney's link to this case: Law360 attorney profile, https://www.law360.com/firms/nixon-peabody/attorneys/timothy-p-maloney ("April 10, 2026 Omni MedSci, Inc. v. Oura Health Oy, Texas Eastern").
• Continuity of the Nixon Peabody team: docket for Omni MedSci, Inc. v. Samsung Elecs. Co. et al., No. 2:24-cv-01070-JRG-RSP (E.D. Tex.), Dkts. 8–13 (Jan. 13, 2025) — appearances by Stringfield, Maloney, Gjorgiev, Krusiewicz, Chiaviello, Holt: https://dockets.justia.com/docket/texas/txedce/2:2024cv01070/[235014](/patent/235014).
• Plaintiff's full appearance roster as of the Sept. 2025 calendar call (Davis, Chiaviello, Georgiev, Holt, Krusiewicz, Maloney, Stringfield, Wilson representing Omni; Mayer Brown and Sheppard Mullin representing Oura): CM/ECF printout reproduced as Ex. 1079 in IPR2025-00995, https://www.docketalarm.com/cases/PTAB/IPR2025-00995/Samsung_Electronics_Co._Ltd._v._W%26Wsens_Devices_Inc/09-24-2025-Petitioner/Exhibit-1079-Gilstrap_August_2026_All_Case_Types/.
• PTAB roles: Omni MedSci's Power of Attorney in IPR2025-01250 (Jennifer Hayes lead; Stringfield, Maloney, Christopher, Holt, Georgiev, Leggett back-up), https://www.docketalarm.com/cases/PTAB/IPR2025-01250/SAMSUNG_ELECTRONICS_CO._LTD._v._OMNI_MEDSCI_INC/docs/08-26-2025-Patent_Owner/Notice__Power_of_Attorney-8-Notice_Power_of_Attorney.pdf.
• Why a 2026 Oura-only refiling makes sense: On 3/31/2026 Judge Gilstrap adopted Magistrate Judge Payne's R&R and granted Oura's motion to dismiss the Third Amended Complaint as to improper joinder in 2:24-cv-01070, denying it otherwise — i.e., Oura was severed out twelve days before this case was filed. Order text at https://www.govinfo.gov/content/pkg/USCOURTS-txed-2_24-cv-01070/pdf/USCOURTS-txed-2_24-cv-01070-0.pdf. That procedural posture strongly supports the inference that 2:26-cv-00289 is Omni's re-filed, single-defendant action against Oura, staffed by the same Nixon Peabody + Davis Firm team.

Caveats you should carry forward

1. No confirmed appearances in 2:26-cv-00289 itself. Maloney is the only attorney I can independently tie to the case number, and via a third-party database (Law360), not the docket. If appearances were filed in April–October 2026, I could not retrieve them; if Oura's counsel moved to dismiss and briefing is underway, the operative appearances would be in that record.
2. Counsel attribution risk: it is possible Omni has added or substituted counsel for the Oura-only case (e.g., a different Nixon Peabody partner as first-chair, or an additional local firm). Do not rely on the above as a docket-certified list.
3. Patent mismatch in the public summaries: the case metadata lists U.S. Patent No. 11,596,311, but the third-party "complaint analysis" for this docket number discusses the '868 and '533 patents and claims 1, 5–8, 11–13 — language that tracks Omni's 2024 complaint. I could not verify which patent(s) Dkt. 1 actually asserts, and no source I found confirms '311's role.
4. No in-house counsel identified. Omni is a small IP-holding company; Oura's Chief Legal Officer Avonte Campinha-Bacote signed Oura's PTAB POA (defendant side), not a plaintiff appearance.

To certify: pull the 2:26-cv-00289 docket report (Dkt. 1 signature block plus all subsequent "NOTICE of Attorney Appearance" entries) from E.D. Tex. CM/ECF, and cross-check the court's published calendar printout for the Gilstrap/Payne docket, which lists every attorney of record by party.

I'll research counsel for Oura Health Oy in this docket and the related proceedings.

Good leads. Let me pull the docket aggregator page and dig into the specific attorneys.

Strong signal that Mayer Brown represents Oura. Let me confirm roles, local counsel, and whether appearances have been filed in the 2026 docket.

Counsel of Record — Defendant Oura Health Oy (No. 2:26-cv-00289, E.D. Tex.)

Bottom line

Oura Health Oy's defense team in this 2026 refiling is Mayer Brown LLP, the same firm that defended Oura in the parent case, No. 2:24-cv-01070-JRG-RSP, until Oura was dismissed for improper joinder on 2026-03-31. The most likely appearances in the new docket are Jasjit S. Vidwan (Washington, DC) and Julia Haines (Washington, DC), with Robert G. Pluta (Chicago) available as PTAB-side backup.

Confidence caveat — read this before relying on it: I could not retrieve a PACER docket sheet or an imaged appearance notice for 2:26-cv-00289 itself. Attorney aggregators (ai-lab.exparte.com, Patexia) return only a case-summary shell for this docket with an empty "Attorney" field, and no docket text. The identifications below therefore rest on (a) Law360 attorney–case linkage records naming this exact case and filing date, (b) confirmed appearances by the same attorneys for Oura in the companion 2026 E.D. Tex. case, No. 2:26-cv-00316 (Zepp Inc. et al v. Oura Health Oy), and (c) continuity of counsel from No. 2:24-cv-01070. That is strong circumstantial evidence, not a docket-sheet confirmation. Treat appearance dates and docket entry numbers as unverified. No in-house Oura counsel has been publicly identified in this case, and I have found no local Texas counsel of record designated for Oura in the 2026 docket.

---

I. Oura Health Oy — defense counsel

Service contact used by Oura's team in the parent case (likely still operative): Oura-Omni@mayerbrown.com.

Local counsel: I found no Texas local counsel identified for Oura in either the parent case's substantive filings or the 2026 docket. Mayer Brown's P.R. 4-2 signature block in No. 2:24-cv-01070 lists only the DC and Chicago offices, with Vidwan and Choi appearing pro hac vice. If Oura follows the same pattern here, expect pro hac vice motions rather than a Texas firm of record — but this should be verified against the docket.

---

II. Important correction — don't confuse plaintiff's counsel with Oura's

Law360 attorney pages for Daniel D. Georgiev (Nixon Peabody) also carry the "April 10, 2026 — Omni MedSci, Inc. v. Oura Health Oy" entry. Georgiev is plaintiff-side counsel, not Oura's. Nixon Peabody LLP is Omni MedSci's own firm: Jennifer Hayes is Omni's lead counsel in the IPRs (Reg. No. 50,845), and Georgiev appears as Omni's back-up counsel on Omni's power of attorney in IPR2025-01250 and in the Director Review caption in IPR2025-01253.

For completeness, Omni's likely 2026-side team, by continuity from No. 2:24-cv-01070:

• Nixon Peabody LLP — Daniel S. Stringfield (Chicago), Jennifer Hayes (Los Angeles), Timothy Maloney, Angelo J. Christopher, Benjamin R. Holt (DC), Daniel Georgiev (Chicago); listed as "Attorneys for Plaintiff Omni MedSci, Inc." on the 2025-11-21 Joint Claim Construction and Prehearing Statement.
• The Davis Firm, P.C. (Longview, TX) — William E. Davis III and Ty William Wilson, Omni's Texas local counsel; the Omni-side service address in the parent case was OMNI-DF@davisfirm.com, and the Justia docket for the related No. 2:25-cv-00483 shows Davis and Wilson appearing for Omni.

---

III. Data-quality flags

1. Complaint-analysis contamination. The Ex Parte "complaint analysis" page for 2:26-cv-00289 charts infringement of U.S. Patents 9,055,868 and 9,651,533 and references the '304 and '475 patents — i.e., the parent case's patent set, not the '311 patent that the case metadata identifies as the sole patent at issue. Do not treat that page's asserted-claims section (claims 1, 5–8, 11–13 of the '868) as describing this complaint. The metadata controls on the patent; the aggregator page appears to have ingested the 2024 complaint.
2. Existing summary vs. metadata. The prior summary correctly noted the narrative didn't list asserted patents; the metadata supplies U.S. Patent No. 11,596,311. Nothing in the counsel research above conflicts with that.
3. Status. Ex Parte and Patexia both show the case filed 2026-04-10 and "Open," consistent with the prior section's finding of no merits rulings.

---

IV. What to verify on PACER (I could not)

• The